HTB homepage • Conference reports • Articles by subject • Subscribe June 2018 Contents Editorial 29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports 08 June 2018: vol 19 no 10: DTG alert and PK reports Treatment alerts New contraindication against using darunavir/cobicistat during pregnancy Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide) BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception Supplements Introduction to ART (May 2018) Conference reports 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily Vaginal ring reduces efavirenz but not atazanavir exposures Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations Antiretrovirals China approves albuvirtide: a once-weekly injectable entry inhibitor Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option Side effects Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir Coinfections and complications RITA: issue on lung health HIV prevention and transmission New FDA guidance for developing PrEP drugs UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people Broad PrEP access in Australia reduces HIV infections even with reduced condom use by people not on PrEP Webcasts on PrEP and women Cure-related research Cure research: open access publications Online database of more than 200 studies on HIV cure research Community survey on treatment interruptions (ATIs) in cure research On the web US community call for coalition for long-term survivors Sexual identity and HIV Modern ART in Africa: new resources PDFs 29 June 2018: vol 19 no 11 08 June 2018: vol 19 no 10 HTB homepage • Conference reports • Articles by subject • Subscribe
